InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.00
(
0.79%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.05
(
0.70%
)
Bitcoin
59,922.52
(
-3.39%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Bio_pete

Send PM Follow Ignore
Followers 17
Posts 1580
Boards Moderated 0
Alias Born 02/07/2007

Bio_pete

Re: ronpopeil post# 84839

Sunday, 12/28/2014 6:19:26 PM

Sunday, December 28, 2014 6:19:26 PM

Post# of 97239
CYNAF - Jason Napodano has done a good job of explaining why apomorphine is a better therapeutic approach in treating off episodes then levodopa. Its going to take years before we'll know if Acorda overpaid but I have a hard time believing the inhaler will capture a larger market share then CYNAF's strip. If I was ACAD then I'd buy them out right now.

I also think the inhaler is a bad choice for this patient population. Your already talking about a group of patients will poor respiratory function so why introduce a foreign substance?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up